Elizabeth M. Gore, MD

Publications

• Veteran oropharyngeal cancer outcomes in the modern era: a multi-institutional retrospective analysis.

  (Little S, Williams MF, Gilkey M, Perez-Bello D, Amadio G, Klein M, Block A, Gore E, Chang M, Duvvuri U, Nance MA, Becker DJ, Takiar V, Flanagan CE, Schwartzman L, Madabhushi A, Sandulache VC.) Oral Oncol. 2026 Mar 18;176:107942 PMID: 41855673 03/20/2026

• Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

  (Kachnic LA, Moughan J, Hong TS, Haddock MG, Tahir N, Yoon HH, Diaz DA, Anderson CM, Seaward SA, Lominska CE, O'Brien PE, Chen Y, Salo JC, Christie AD, Dorth JA, Aljumaily RM, Gore EM, Winter KA, Safran HP, Movsas B.) Cancer. 2026 Mar 15;132(6):e70345 PMID: 41808581 03/11/2026

• Impact of Neoadjuvant Induction Chemotherapy Prior to Chemoradiation on Survival and Surgical Outcomes in Real-World Esophageal Adenocarcinoma Cohort.

  (Matoska TM, Memon AA, Acevedo Moreno LA, Bulacan C, Rein L, Banerjee A, George B, Jurkowski L, Phan A, Johnstone C, Shukla ME, Gore EM, Linsky P, Gasparri M, Hunt M, Puckett LL.) Cancers (Basel). 2026 Jan 09;18(2) PMID: 41595134 PMCID: PMC12838675 SCOPUS ID: 2-s2.0-105029137974 01/28/2026

• Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma

  (Kachnic LA, Moughan J, Hong TS, Haddock MG, Tahir N, Yoon HH, Diaz DA, Anderson CM, Seaward SA, Lominska CE, O’Brien PE, Chen Y, Salo JC, Christie AD, Dorth JA, Aljumaily RM, Gore EM, Winter KA, Safran HP, Movsas B.) Cancer. 15 March 2026;132(6) SCOPUS ID: 2-s2.0-105032449671 03/15/2026

• Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.

  (Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL.) J Clin Oncol. 2025 Nov 10;43(32):3494-3504 PMID: 40239134 PMCID: PMC12228211 SCOPUS ID: 2-s2.0-105004600350 04/16/2025

• Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.

  (Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, Bahary JP, Pisansky TM, Zeitzer KL, Gore E, Efstathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong A, Dess RT, McGinnis LS, Kuettel M, DeMora L, Sandler HM.) Prostate. 2025 Oct;85(14):1315-1322 PMID: 40686005 PMCID: PMC12366761 SCOPUS ID: 2-s2.0-105011074274 07/21/2025

• Radiobiologically equivalent deformable dose mapping for re-irradiation planning: Implementation, robustness, and dosimetric benefits.

  (García-Alvarez JA, Paulson E, Kainz K, Puckett L, Shukla ME, Zhu F, Gore E, Tai A.) Radiother Oncol. 2025 Apr;205:110741 PMID: 39855600 SCOPUS ID: 2-s2.0-85216209940 01/25/2025

• 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies.

  (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) Commun Med (Lond). 2025 Mar 04;5(1):61 PMID: 40038525 PMCID: PMC11880319 SCOPUS ID: 2-s2.0-86000110322 03/05/2025

• Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

  (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY.) Int J Radiat Oncol Biol Phys. 2024 Dec 01;120(5):1461 PMID: 39320298 PMCID: PMC11698260 SCOPUS ID: 2-s2.0-85204708740 09/25/2024

• Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

  (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW.) Qual Life Res. 2024 Oct;33(10):2833-2844 PMID: 39066879 PMCID: PMC11577575 SCOPUS ID: 2-s2.0-85200043165 07/28/2024

• Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.

  (Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA.) Eur Urol Focus. 2024 Mar;10(2):271-278 PMID: 38307806 PMCID: PMC11257781 SCOPUS ID: 2-s2.0-85184044805 02/03/2024

• High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab

  (Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, Klawikowski S, Livingston K, Longo JM, Menon S, Ortiz de Choudens S, Puckett L, Retseck J, Shukla M, Thompson J, Gore E.) Jto Clinical and Research Reports. December 2024;5(12) SCOPUS ID: 2-s2.0-85207777055 12/01/2024